by Mowbray C, Braillard S, Speed W, Glossop P, Whitlock G, Gibson K, Mills J, Brown A, Gardner JM, Cao Y, Hua W, Morgans G, Feijens P-B, Matheeussen A, Maes L. Journal of Medicinal Chemistry.
DOI: 10.1021/acs.jmedchem.5b01456
Summary: Visceral leishmaniasis is a severe parasitic disease that is one of the most neglected tropical diseases. Treatment options are limited, and there is an urgent need for new therapeutic agents. Following an HTS campaign and hit optimization, a novel series of amino-pyrazole ureas has been identified with potent in vitro antileishmanial activity. Furthermore, compound 26 shows high levels of in vivo efficacy (>90%) against Leishmania infantum, thus demonstrating proof of concept for this series.
